Business
SAB Biotherapeutics Announces First Publication of Promising Nonclinical Data for SAB-183 Against Pneumonic Plague in the Journal Antibodies
In study conducted for U.S. Army Medical Research Institute, SAB-183 demonstrated strong immune protection and response against Yersinia pestis infection,
About this update from Sab Biotherapeutics, Inc.
[{"type":"text","content":"In study conducted for U.S. Army Medical Research Institute, SAB-183 demonstrated strong immune protection and response against Yersinia pestis infection, which causes plague Findings demonstrate utility of Transchromosomic (Tc) bovine generated fully-human immunoglobulin (or polyclonal) antibodies as a strategy to provide broad protection against infections caused by drug-resistant, highly mutating pathogens First data demonstrating multi-epitope binding broadly neutralizing activity against bacterial infections, builds on prior data demonstrating efficacy against viral infections SIOUX FALLS, S.D., May 12, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human immunoglobulin (hIgG) antibodies, also known as fully-human polyclonal antibodies, without the need for human donors, today announced the publication of nonclinical data in the medical journal Antibodies. The data are from a study conducted in collaboration with the United States Army Medical Research Institute of Infectious Diseases (USAMRID) highlighting that fully-human immunoglobulins derived from Tc bovines can protect mice from Yersinia pestis, a Tier 1 select bacterial biothreat agent that can rapidly cause fatal infections and is associated with pneumonic plague as well as bubonic plague. The article, “Polyclonal antibodies derived from transchromosomic bovines vaccinated with the recombinant F1-V vaccine increase bacterial opsonization in vitro and protect mice from pneumonic plague,” was published online in the 10th anniversary special issue of Antibodies. SAB-183, the Tc bovine derived fully-human immunoglobulin, demonstrated increased opsonization and phagocytosis of Y. pestis in vitro and elicited a strong immune response with significant protection to mice exposed to Y. pestis in vivo. Y. pestis is a major biothreat due to its capacity for aerosol dissemination and its highly contagious nature in the pneumonic form. Furthermore, as the study notes, drug-resistant isolates of Y. pestis are on the rise and constitute a significant concern for the public health and biodefense communities. In lieu of any approved vaccine for this pathogen, effective antibody therapies and other countermeasures are needed to e...